Advertisement

Pathologic Features, Grading, and Variants of Follicular Lymphoma

  • Ali Sakhdari
  • Roberto N. MirandaEmail author
Chapter

Abstract

Follicular lymphoma (FL) encompasses a wide spectrum of clinical and pathologic manifestations ranging from a mostly indolent neoplasm to more aggressive types. It was initially described as a nodular lymphoma predominantly composed of B-lymphocytes residing in the germinal center which were morphologically defined as small centrocytes and large centroblasts. The genetic basis of the disease is the presence of the translocation t(14;18)(q32;q21)/IGH-BCL2 that encodes for a fusion protein with potent antiapoptotic characteristic. Although mainly an indolent lymphoma, in a substantial minority of cases, transformation to a more aggressive lymphoma occurs. Multiple variants of follicular lymphoma have been described mainly based on clinical manifestations, patterns of organ involvement, age of patients, and cytogenetic or molecular abnormalities. This has led to the formal recognition of variants of follicular lymphoma such as testicular, primary cutaneous, or duodenal follicular lymphoma. Some of these variants along with high-grade FL may lack t(14;18)(q32;q21)/IGH-BCL2. Similarly, pediatric-type FL (PTFL) affects children and lacks t(14;18)(q32;q21)/IGH-BCL2. A rare variant, diffuse FL, by definition, lacks follicles so it challenges the essential concept that defines follicular lymphoma as a nodular neoplasm. In this chapter, we cover the morphologic spectrum, immunophenotype, cytogenetics, and molecular genetic features as well as the common variants of follicular lymphoma.

Keywords

Follicular lymphoma IGH-BCL2 Centrocytes Centroblasts Fluorescence in situ hybridization (FISH) Diffuse follicular lymphoma Duodenal-type follicular lymphoma 

References

  1. 1.
    Medeiros LJ, O’Malley DP, Caraway NP, Vega F, Elenitoba-Johnson KJS, Lim MS. Tumors of the lymph nodes and spleen. In: Atlas of tumor pathology, Series 4. AFIP; 2017.Google Scholar
  2. 2.
    Jaffe ES, Harris NL, Swerdlow SH, Ott G, Nathwani BN, Jong Dd, et al. Follicular lymphoma. In: Swerdlow SH, Campo E, Harris NH, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon: IARC; 2017. p. 266–77.Google Scholar
  3. 3.
    Brill NE, Baehr G, Rosenthal N. Generalized giant lymph follicle hyperplasia of lymph nodes and spleen; a hitherto undescribed type. Am J Med. 1952;13:570–4.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    Symmers D. Lymphoid diseases; Hodgkin’s granuloma, giant follicular lymphadenopathy, lymphoid leukemia, lymphosarcoma and gastrointestinal pseudoleukemia. Arch Pathol (Chic). 1948;45:73–131.Google Scholar
  5. 5.
    Custer RP. Borderlands dim in malignant disease of the blood-forming organs. Radiology. 1953;61:764–70.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Cohen SE, Bergstrom VW. Giant follicular lymphoblastoma. Am J Clin Pathol. 1946;16:22–39.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Hicks EB, Rappaport H, Winter WJ. Follicular lymphoma; a re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer. 1956;9:792–821.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Gall EA, Mallory TB. Malignant lymphoma: a clinico-pathologic survey of 618 cases. Am J Pathol. 1942;18:381–429.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Lennert K. Morphology and classification of malignant lymphomas and so-called reticuloses. Acta Neuropathol Suppl. 1975;Suppl 6:1–16.Google Scholar
  10. 10.
    Lukes RJ, Collins RD. New approaches to the classification of the lymphomata. Br J Cancer Suppl. 1975;2:1–28.PubMedPubMedCentralGoogle Scholar
  11. 11.
    National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. The non-Hodgkin’s lymphoma pathologic classification project. Cancer. 1982;49:2112–35.Google Scholar
  12. 12.
    Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–92.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. World Health Organization classification of tumors. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.Google Scholar
  14. 14.
    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO Classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon (France): IARC; 2017.Google Scholar
  15. 15.
    Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159–69.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Gradowski JF, Jaffe ES, Warnke RA, Pittaluga S, Surti U, Gole LA, Swerdlow SH. Follicular lymphomas with plasmacytic differentiation include two subtypes. Mod Pathol. 2010;23:71–9.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Miranda RN. Extranodal follicular lymphoma. In: Medeiros LJ, editor. Diagnostic pathology lymph nodes and spleen with extranodal lymphomas. 1st ed. Altona: Amirsys, Inc; 2011. p. 7-12 to 7-23.Google Scholar
  18. 18.
    Medeiros LJ, Miranda RN. Diagnostic pathology: lymph nodes and extranodal lymphomas. 2nd ed. Salt Lake City: Elsevier; 2017.Google Scholar
  19. 19.
    Kojima M, Matsumoto M, Miyazawa Y, Shimizu K, Itoh H, Masawa N. Follicular lymphoma with prominent sclerosis (“sclerosing variant of follicular lymphoma”) exhibiting a mesenteric bulky mass resembling inflammatory pseudotumor. Report of three cases. Pathol Oncol Res. 2007;13:74–7.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Kim H, Dorfman RF, Rappaport H. Signet ring cell lymphoma. A rare morphologic and functional expression of nodular (follicular) lymphoma. Am J Surg Pathol. 1978;2:119–32.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Bouska A, Zhang W, Gong Q, Iqbal J, Scuto A, Vose J, et al. Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma. Leukemia. 2017;31:83–91.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Schmid U, Cogliatti SB, Diss TC, Isaacson PG. Monocytoid/marginal zone B-cell differentiation in follicle centre cell lymphoma. Histopathology. 1996;29:201–8.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Jaffe ES, Arber DA, Campo E, Harris NL, Quintanilla-Martinez L, editors. Hematopathology. 2nd ed. Philadelphia, PA: Elsevier; 2016.Google Scholar
  24. 24.
    Osborne BM, Butler JJ. Follicular lymphoma mimicking progressive transformation of germinal centers. Am J Clin Pathol. 1987;88:264–9.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Kojima M, Yamanaka S, Yoshida T, Shimizu K, Murayama K, Ohno Y, et al. Histological variety of floral variant of follicular lymphoma. APMIS. 2006;114:626–32.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Goates JJ, Kamel OW, LeBrun DP, Benharroch D, Dorfman RF. Floral variant of follicular lymphoma. Immunological and molecular studies support a neoplastic process. Am J Surg Pathol. 1994;18:37–47.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Pina-Oviedo S, Miranda RN, Lin P, Manning JT, Medeiros LJ. Follicular lymphoma with hyaline-vascular Castleman-like features: analysis of 6 cases and review of the literature. Hum Pathol. 2017;68:136–46.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Younes SF, Beck AH, Lossos IS, Levy R, Warnke RA, Natkunam Y. Immunoarchitectural patterns in follicular lymphoma: efficacy of HGAL and LMO2 in the detection of the interfollicular and diffuse components. Am J Surg Pathol. 2010;34:1266–76.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Mann RB, Berard CW. Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method. Hematol Oncol. 1983;1:187–92.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    El Behery R, Laurini JA, Weisenburger DD, Smith LM, Dave BJ, Yuan J, et al. Follicular large cleaved cell (centrocytic) lymphoma: an unrecognized variant of follicular lymphoma. Hum Pathol. 2018;72:180–90.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Montes-Moreno S, Roncador G, Maestre L, Martinez N, Sanchez-Verde L, Camacho FI, et al. Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas. Blood. 2008;111:351–8.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Wang SA, Wang L, Hochberg EP, Muzikansky A, Harris NL, Hasserjian RP. Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features. Am J Surg Pathol. 2005;29:1490–6.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Li Y, Hu S, Zuo Z, Hong M, Lin P, Li S, et al. CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. Mod Pathol. 2015;28:787–98.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Mackrides N, Campuzano-Zuluaga G, Maque-Acosta Y, Moul A, Hijazi N, Ikpatt FO, et al. Epstein-Barr virus-positive follicular lymphoma. Mod Pathol. 2017;30:519–29.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Lambrechts AC, Hupkes PE, Dorssers LC, van’t Veer MB. Translocation (14;18)-positive cells are present in the circulation of the majority of patients with localized (stage I and II) follicular non-Hodgkin’s lymphoma. Blood. 1993;82:2510–6.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Nadel B, Marculescu R, Le T, Rudnicki M, Bocskor S, Jager U. Novel insights into the mechanism of t(14;18)(q32;q21) translocation in follicular lymphoma. Leuk Lymphoma. 2001;42:1181–94.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Horsman DE, Gascoyne RD, Coupland RW, Coldman AJ, Adomat SA. Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t(14; 18) in follicular lymphoma. Am J Clin Pathol. 1995;103:472–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Watanabe R, Tomita N, Matsumoto C, Hattori Y, Matsuura S, Takasaki H, et al. The 3q27 and 18q21 translocations for follicular lymphoma and diffuse large B-cell lymphoma in the rituximab era. J Clin Exp Hematop. 2013;53:107–14.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Karube K, Ying G, Tagawa H, Niino D, Aoki R, Kimura Y, et al. BCL6 gene amplification/3q27 gain is associated with unique clinicopathological characteristics among follicular lymphoma without BCL2 gene translocation. Mod Pathol. 2008;21:973–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Akasaka T, Lossos IS, Levy R. BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood. 2003;102:1443–8.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Green MR, Gentles AJ, Nair RV, Irish JM, Kihira S, Liu CL, et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood. 2013;121:1604–11.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Ottensmeier CH, Thompsett AR, Zhu D, Wilkins BS, Sweetenham JW, Stevenson FK. Analysis of VH genes in follicular and diffuse lymphoma shows ongoing somatic mutation and multiple isotype transcripts in early disease with changes during disease progression. Blood. 1998;91:4292–9.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Jegalian AG, Eberle FC, Pack SD, Mirvis M, Raffeld M, Pittaluga S, Jaffe ES. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood. 2011;118:2976–84.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Zenda T, Masunaga T, Fuwa B, Okada T, Ontachi Y, Kondo Y, et al. Small follicular lymphoma arising near the ampulla of vater: a distinct subtype of duodenal lymphoma? Int J Gastrointest Cancer. 2005;36:113–9.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Kitabatake H, Nagaya T, Tanaka N, Ota H, Sano K, Asano N, et al. Development of diffuse large B-cell lymphoma from follicular lymphoma of the duodenum: changes in endoscopic findings during a 6-year follow-up. Clin J Gastroenterol. 2017;10:79–85.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Seki A, Iwamuro M, Yoshioka M, Fujii N, Okada H, Nose S, et al. Primary duodenal follicular lymphoma treated with rituximab monotherapy and followed-up for 15 years. Acta Med Okayama. 2015;69:301–6.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Takata K, Tanino M, Ennishi D, Tari A, Sato Y, Okada H, et al. Duodenal follicular lymphoma: comprehensive gene expression analysis with insights into pathogenesis. Cancer Sci. 2014;105:608–15.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Louissaint A Jr, Ackerman AM, Dias-Santagata D, Ferry JA, Hochberg EP, Huang MS, et al. Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement. Blood. 2012;120:2395–404.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Liu Q, Salaverria I, Pittaluga S, Jegalian AG, Xi L, Siebert R, et al. Follicular lymphomas in children and young adults: a comparison of the pediatric variant with usual follicular lymphoma. Am J Surg Pathol. 2013;37:333–43.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Schmidt J, Ramis-Zaldivar JE, Nadeu F, Gonzalez-Farre B, Navarro A, Egan C, et al. Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. Blood. 2017;130:323–7.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Ozawa MG, Bhaduri A, Chisholm KM, Baker SA, Ma L, Zehnder JL, et al. A study of the mutational landscape of pediatric-type follicular lymphoma and pediatric nodal marginal zone lymphoma. Mod Pathol. 2016;29:1212–20.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Finn LS, Viswanatha DS, Belasco JB, Snyder H, Huebner D, Sorbara L, et al. Primary follicular lymphoma of the testis in childhood. Cancer. 1999;85:1626–35.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Lones MA, Raphael M, McCarthy K, Wotherspoon A, Terrier-Lacombe MJ, Ramsay AD, et al. Primary follicular lymphoma of the testis in children and adolescents. J Pediatr Hematol Oncol. 2012;34:68–71.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Siddiqi IN, Friedman J, Barry-Holson KQ, Ma C, Thodima V, Kang I, et al. Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations. Mod Pathol. 2016;29:570–81.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Katzenberger T, Kalla J, Leich E, Stocklein H, Hartmann E, Barnickel S, et al. A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood. 2009;113:1053–61.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Zamo A, Pischimarov J, Horn H, Ott G, Rosenwald A, Leich E. The exomic landscape of t(14;18)-negative diffuse follicular lymphoma with 1p36 deletion. Br J Haematol. 2018;180(3):391–4.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Pittaluga S, Harris NL, Siebert R, Salaverria I. Large B-cell lymphoma with IRF4 rearrangement. In: Swerdlow SH, Campo E, Harris NH, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of tumours of the haematopoietic and lymphoid tissues. 4th revised ed. Lyon: IARC; 2017. p. 280–1.Google Scholar
  58. 58.
    Karube K, Guo Y, Suzumiya J, Sugita Y, Nomura Y, Yamamoto K, et al. CD10-MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features. Blood. 2007;109:3076–9.CrossRefGoogle Scholar
  59. 59.
    Naresh KN. MUM1 expression dichotomises follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes. Haematologica. 2007;92:267–8.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Medeiros LJ, OMalley DP, Caraway N, Vega F, Elenitoba-Johnson KSJ, Lim MS. Tumors of the lymph nodes and spleen. AFIP; 2017.Google Scholar
  61. 61.
    Sorigue M, Sancho JM. Current prognostic and predictive factors in follicular lymphoma. Ann Hematol. 2018;97:209–27.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Kanagal-Shamanna R, Medeiros LJ, Lu G, Wang SA, Manning JT, Lin P, et al. High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis. Histopathology. 2012;61:945–54.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Wafa A, Moassass F, Liehr T, Bhatt S, Aljapawe A, Al AW. A high complex karyotype involving eleven chromosomes including three novel chromosomal aberrations and monoallelic loss of TP53 in case of follicular lymphoma transformed into B-cell lymphoblastic leukemia. Mol Cytogenet. 2016;9:91.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Kridel R, Sehn LH, Gascoyne RD. Can histologic transformation of follicular lymphoma be predicted and prevented? Blood. 2017;130:258–66.CrossRefGoogle Scholar
  65. 65.
    O’Shea D, O’Riain C, Taylor C, Waters R, Carlotti E, Macdougall F, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood. 2008;112:3126–9.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Pasqualucci L, Khiabanian H, Fangazio M, Vasishtha M, Messina M, Holmes AB, et al. Genetics of follicular lymphoma transformation. Cell Rep. 2014;6:130–40.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16:1111–22.CrossRefGoogle Scholar
  68. 68.
    Gentles AJ, Alizadeh AA, Lee SI, Myklebust JH, Shachaf CM, Shahbaba B, et al. A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood. 2009;114:3158–66.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Cooper K, Haffajee Z. bcl-2 and p53 protein expression in follicular lymphoma. J Pathol. 1997;182:307–10.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Canioni D, Joseph L, Fabiani B, Chassagne-Clement C, Dartigues-Cuilleres P, Charlotte F, et al. Prognostic value of P53 and Myc protein expression in follicular lymphomas in the PRIMA Trial in the Lysa Group. Blood. 2017;130:1508.Google Scholar
  71. 71.
    Davies AJ, Lee AM, Taylor C, Clear AJ, Goff LK, Iqbal S, et al. A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. Leukemia. 2005;19:1459–65.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Miao Y, Hu SM, Lu XY, Li SY, Wang W, Medeiros LJ, Lin P. Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature. Hum Pathol. 2016;58:72–7.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114:2273–9.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Aukema SM, van Pel R, Nagel I, Bens S, Siebert R, Rosati S, et al. MYC expression and translocation analyses in low-grade and transformed follicular lymphoma. Histopathology. 2017;71:960–71.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.The University of Texas MD Anderson Cancer Center, Department of HematopathologyHoustonUSA
  2. 2.University of TorontoTorontoCanada

Personalised recommendations